How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Eric Ruderman, MD

Eric Ruderman, MD

Professor of Medicine
Division of Rheumatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois